Hua Med­i­cine reaps $110.5M, ad­just­ing ex­pec­ta­tions for Hong Kong IPO

→ Shang­hai-based di­a­betes drug­mak­er Hua Med­i­cine has con­clud­ed its Hong Kong IPO with a $110.5 mil­lion (HK$867 mil­lion) raise by pric­ing at the low end of its range. Now val­ued at $1.1 bil­lion, Hua was the sec­ond com­pa­ny to take ad­van­tage of the city’s new rules al­low­ing pre-rev­enue biotechs to list on it stock ex­change. Like As­cle­tis and BeiGene (which jumped the line with its sec­ondary list­ing) be­fore it, its shares fell ini­tial­ly, but end­ed its first trad­ing day at the IPO price. Hua is as­sign­ing al­most 70% of its IPO pro­ceeds to dorza­gli­atin, the drug it bought from Roche in 2011 and has since pushed to Phase III.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER